摘要
目的研究维兰特罗/乌美溴铵联合罗氟司特对慢性阻塞性肺病(COPD)患者肺功能和改良英国医学研究组理事会呼吸困难指数(mMRC)评分的影响。方法COPD患者120例随机分为观察组以及对照组各60例,均采用维兰特罗/乌美溴铵进行治疗,观察组在此基础上联合采用罗氟司特进行治疗,比较两组治疗效果、肺功能、mMRC评分、免疫功能及不良反应。结果观察组治疗总有效率高于对照组(P<0.05);治疗后两组用力呼气量(FEV)、第1秒用力呼气量(FEV1)、第1秒用力呼气量占用力肺活量百分率(FEV1%)升高,且观察组高于对照组(P<0.05);观察组mMRC评分低于对照组(P<0.05);治疗后两组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平显著升高,且观察组高于对照组(P<0.05)。结论维兰特罗/乌美溴铵联合罗氟司特治疗COPD患者其肺功能以及mMRC评分显著改善,建议临床推广。
Aim To study the effects of vilanterol/umenium bromide combined with roflukast on pulmonary function and modified British medical research council(mMRC)grade in patients with chronic obstructive pulmonary disease(COPD).Methods 120 patients with COPD were randomly divided into observation group and control group,with 60 cases in each group.The observation group was treated with vilanterol/omepramine.On this basis,the observation group was treated with roflukast.The therapeutic effects,pulmonary function,MMRC score,immune function and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was higher than that of the control group(P<0.05);After treatment,forced expiratory volume(FEV),forced expiratory volume in the first second(FEV1)and percentage of FEV1(FEV1%)in the two groups increased,and the observation group was higher than that in the control group(P<0.05);The score of MMRC in the observation group was lower than that in the control group(P<0.05);After treatment,the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in the observation group were significantly higher than those in the control group(P<0.05).Conclusion The lung function and MMRC grade of patients with COPD treated with vilanterol/umenium bromide combined with roflukast are significantly improved,which is recommended to be popularized in clinic.
作者
张挺
张超
于波
ZHANG Ting;ZHANG Chao;YU Bo(Respiratory Department,Beijing Shunyi District Hospital,Beijing 101300,China;Pulmonary Function Rooms,Beijing Shunyi District Hospital,Beijing 101300,China;Laboratory,Beijing Shunyi District Hospital,Beijing 101300,China)
出处
《中南医学科学杂志》
CAS
2022年第4期599-601,共3页
Medical Science Journal of Central South China
